Influenza Vaccine, Live, Nasal, Freeze-dried

Asset

Live attenuated influenza vaccine stimulating mucosal and systemic immunity against influenza viruses

Stage: Phase 3
Modality: Vaccine
Target: Not known; 1
Indication: 89
Trials: 1
Developer

Indications

1

Influenza prevention
Phase 3, Unknown, NCT06280144, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Trials89
Evidence for its targets1
Competitors4
Signals4

Every asset’s record: target, stage, trials and the evidence behind it.